PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK EXAGEN INC.Exagen Inc. • August 9th, 2021 • Services-medical laboratories
THIS PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK (the “Warrant”) certifies that, for value received, __________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after __________, 2021 (the “Initial Exercise Date”) and on or prior to the close of business on the date that this Warrant has been exercised in full (the “Termination Date”) to subscribe for and purchase from Exagen Inc., a Delaware corporation (the “Company”), up to __________ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE EXAGEN INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO EXAGEN INC. IF PUBLICLY DISCLOSED....Co-Promotion Agreement • August 9th, 2021 • Exagen Inc. • Services-medical laboratories
As contemplated in the Co-Promotion Agreement between Exagen and Janssen signed December 10, 2018, please find attached the final Baseline TRxU for April through June (3th Quarter) of 2021, which has been agreed upon by the Janssen and Exagen Teams. This Baseline TRxU include CVS/Anthem data for the zip codes covered by Exagen sale representatives as of April 1, 2021, inclusive of the additional zip codes added.
